Quick Answer
Inmune Bio, Inc. reported R&D Expense of $20.66 million for fiscal year 2025.
Inmune Bio, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $20.66M | -37.7% |
| 2024 | $33.17M | +63.6% |
| 2023 | $20.27M | +18.8% |
| 2022 | $17.07M | -16.9% |
| 2021 | $20.54M | +247.1% |
| 2020 | $5.92M | +80.3% |
| 2019 | $3.28M | -2.2% |
| 2018 | $3.35M | +670.6% |
| 2017 | $435.4K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.89M | -51.5% | -15.8% |
| June 30, 2025 | $5.80M | -17.7% | -24.0% |
| March 31, 2025 | $7.64M | -12.1% | -24.1% |
| September 30, 2024 | $10.07M | +68.2% | +42.7% |
| June 30, 2024 | $7.05M | +70.0% | -18.9% |
| March 31, 2024 | $8.69M | +110.3% | +45.2% |
| September 30, 2023 | $5.99M | +16.0% | +44.3% |
| June 30, 2023 | $4.15M | -1.0% | +0.4% |
- Inmune Bio, Inc. showed a decrease of -37.7% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Inmune Bio, Inc.’s r&d expense has grown by 4645.2% (from $435.4 thousand to $20.66 million).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: